

Maria Zambon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6653194/publications.pdf>

Version: 2024-02-01

195
papers

26,380
citations

18887

64
h-index

9118

149
g-index

208
all docs

208
docs citations

208
times ranked

40673
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. <i>Eurosurveillance</i> , 2020, 25, . | 3.9 | 5,865 |
| 2 | Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594. | 13.9 | 2,411 |
| 3 | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546. | 13.9 | 1,709 |
| 4 | Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. <i>Journal of Virology</i> , 2013, 87, 7790-7792. | 1.5 | 1,012 |
| 5 | Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. <i>Lancet</i> , The, 2010, 375, 1100-1108. | 6.3 | 676 |
| 6 | COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. <i>Lancet</i> , The, 2021, 397, 1725-1735. | 6.3 | 658 |
| 7 | Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 183-195. | 4.6 | 585 |
| 8 | SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). <i>Lancet</i> , The, 2021, 397, 1459-1469. | 6.3 | 557 |
| 9 | Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350. | 13.9 | 501 |
| 10 | Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1034-1042. | 4.6 | 493 |
| 11 | Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 445-454. | 5.2 | 341 |
| 12 | Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2395-2402. | 1.4 | 333 |
| 13 | Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007-08 Season. <i>Emerging Infectious Diseases</i> , 2009, 15, 552-560. | 2.0 | 316 |
| 14 | Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. <i>Journal of Clinical Investigation</i> , 2008, 118, 4036-4048. | 3.9 | 299 |
| 15 | Late Ebola virus relapse causing meningoencephalitis: a case report. <i>Lancet</i> , The, 2016, 388, 498-503. | 6.3 | 291 |
| 16 | Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. <i>Eurosurveillance</i> , 2012, 17, 20290. | 3.9 | 278 |
| 17 | Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2264-2272. | 1.4 | 276 |
| 18 | Human Metapneumovirus as a Cause of Community-Acquired Respiratory Illness. <i>Emerging Infectious Diseases</i> , 2002, 8, 897-901. | 2.0 | 265 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Severe and unrecognised: pertussis in UK infants. <i>Archives of Disease in Childhood</i> , 2003, 88, 802-806. | 1.0 | 244 |
| 20 | The mechanism of resistance to favipiravir in influenza. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11613-11618. | 3.3 | 243 |
| 21 | Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7962-7967. | 3.3 | 242 |
| 22 | Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1422-1431. | 2.5 | 229 |
| 23 | Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e354-e365. | 3.4 | 216 |
| 24 | Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10473-10478. | 3.3 | 198 |
| 25 | Global outbreak of severe <i>Mycobacterium chimaera</i> disease after cardiac surgery: a molecular epidemiological study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1033-1041. | 4.6 | 198 |
| 26 | Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network. <i>Journal of Clinical Microbiology</i> , 2003, 41, 742-750. | 1.8 | 193 |
| 27 | Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 240-248. | 4.6 | 186 |
| 28 | Immunogenicity of vaccination against influenza, <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> type B in patients with multiple myeloma. <i>British Journal of Cancer</i> , 2000, 82, 1261-1265. | 2.9 | 173 |
| 29 | Antibody-based assay discriminates Zika virus infection from other flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8384-8389. | 3.3 | 161 |
| 30 | Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 349-359. | 5.2 | 161 |
| 31 | Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children. <i>Clinical Infectious Diseases</i> , 2009, 48, 389-396. | 2.9 | 160 |
| 32 | Diagnosis of Influenza in the Community. <i>Archives of Internal Medicine</i> , 2001, 161, 2116. | 4.3 | 153 |
| 33 | COVID-19 in children: analysis of the first pandemic peak in England. <i>Archives of Disease in Childhood</i> , 2020, 105, 1180-1185. | 1.0 | 152 |
| 34 | Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , 2016, 17, 204-213. | 7.0 | 148 |
| 35 | Position statement: global neuraminidase inhibitor susceptibility network. <i>Antiviral Research</i> , 2001, 49, 147-156. | 1.9 | 142 |
| 36 | A sensitive retroviral pseudotype assay for influenza H5N1 neutralizing antibodies. <i>Influenza and Other Respiratory Viruses</i> , 2007, 1, 105-112. | 1.5 | 142 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Insidious Risk of Severe <i>Mycobacterium chimaera</i> Infection in Cardiac Surgery Patients. <i>Clinical Infectious Diseases</i> , 2017, 64, 335-342. | 2.9 | 129 |
| 38 | Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. <i>International Journal of Epidemiology</i> , 2021, 50, 1124-1133. | 0.9 | 124 |
| 39 | A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624. | 6.0 | 124 |
| 40 | Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 699-711. | 5.2 | 122 |
| 41 | SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181. | 0.9 | 122 |
| 42 | Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. <i>EClinicalMedicine</i> , 2021, 39, 101064. | 3.2 | 116 |
| 43 | Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , 2021, 398, 223-237. | 6.3 | 110 |
| 44 | The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. <i>European Journal of Epidemiology</i> , 1999, 15, 467-473. | 2.5 | 103 |
| 45 | The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. <i>PLoS ONE</i> , 2019, 14, e0222381. | 1.1 | 102 |
| 46 | Evolutionary Dynamics of Local Pandemic H1N1/2009 Influenza Virus Lineages Revealed by Whole-Genome Analysis. <i>Journal of Virology</i> , 2012, 86, 11-18. | 1.5 | 101 |
| 47 | Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. <i>Molecular Therapy</i> , 2014, 22, 233-238. | 3.7 | 101 |
| 48 | Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. <i>Lancet Infectious Diseases</i> , 2011, 11, 91-101. | 4.6 | 90 |
| 49 | Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. <i>Journal of Infection</i> , 2022, 84, 675-683. | 1.7 | 87 |
| 50 | Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom. <i>Journal of Virology</i> , 2014, 88, 13269-13283. | 1.5 | 84 |
| 51 | Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines: Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum Given Concomitantly with Influenza Vaccine to High-Risk Elderly Individuals. <i>Journal of Infectious Diseases</i> , 2008, 198, 1317-1326. | 1.9 | 83 |
| 52 | Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. <i>Eurosurveillance</i> , 2015, 20, . | 3.9 | 83 |
| 53 | Open source clinical science for emerging infections. <i>Lancet Infectious Diseases</i> , 2014, 14, 8-9. | 4.6 | 82 |
| 54 | Seroconversion after influenza vaccination in patients with lung cancer. <i>British Journal of Cancer</i> , 1999, 80, 219-220. | 2.9 | 81 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Molecular Epidemiology of Two Consecutive Outbreaks of Parainfluenza 3 in a Bone Marrow Transplant Unit. <i>Journal of Clinical Microbiology</i> , 1998, 36, 2289-2293. | 1.8 | 81 |
| 56 | SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181. | 0.9 | 81 |
| 57 | Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. <i>EClinicalMedicine</i> , 2020, 26, 100533. | 3.2 | 79 |
| 58 | Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2001, 28, 775-781. | 1.3 | 78 |
| 59 | SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (skIDs): an active, prospective surveillance study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 417-427. | 2.7 | 78 |
| 60 | Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 773-785. | 5.2 | 78 |
| 61 | Subcellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein. <i>Journal of General Virology</i> , 2005, 86, 3303-3310. | 1.3 | 76 |
| 62 | London 2012 Olympic and Paralympic Games: public health surveillance and epidemiology. <i>Lancet</i> , 2014, 383, 2083-2089. | 6.3 | 76 |
| 63 | Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced CoVID-19 outbreak investigations in London care Homes. <i>Journal of Infection</i> , 2020, 81, 621-624. | 1.7 | 74 |
| 64 | Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. <i>Epidemiology and Infection</i> , 2010, 138, 1531-1541. | 1.0 | 73 |
| 65 | Improving influenza vaccine virus selection Report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010. <i>Influenza and Other Respiratory Viruses</i> , 2012, 6, 142-152. | 1.5 | 73 |
| 66 | Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. <i>Antiviral Therapy</i> , 2009, 14, 751-762. | 0.6 | 71 |
| 67 | Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. <i>Transfusion Medicine</i> , 2021, 31, 167-175. | 0.5 | 71 |
| 68 | Estimating influenza vaccine effectiveness using routinely collected laboratory data. <i>Journal of Epidemiology and Community Health</i> , 2010, 64, 1062-1067. | 2.0 | 69 |
| 69 | Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14. <i>Eurosurveillance</i> , 2014, 19, 20959. | 3.9 | 68 |
| 70 | Response to influenza immunisation during treatment for cancer. <i>Archives of Disease in Childhood</i> , 2001, 84, 496-500. | 1.0 | 66 |
| 71 | Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e18606. | 1.2 | 66 |
| 72 | High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. <i>EClinicalMedicine</i> , 2020, 28, 100597. | 3.2 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Restrictions to the Adaptation of Influenza A Virus H5 Hemagglutinin to the Human Host. <i>Journal of Virology</i> , 2004, 78, 502-507. | 1.5 | 61 |
| 74 | <i>Mycobacterium chimaera</i> infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1164-1170. | 2.8 | 60 |
| 75 | Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43,) Tj ETQq1 1 0,784314 rgBT /Ove | 0.9 | 60 |
| 76 | Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?. <i>PLoS ONE</i> , 2016, 11, e0152310. | 1.1 | 58 |
| 77 | Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506. | 2.2 | 58 |
| 78 | A Mouse Model for <i>Betacoronavirus</i> Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant. <i>MBio</i> , 2014, 5, e00047-14. | 1.8 | 55 |
| 79 | Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses. <i>Antiviral Therapy</i> , 2005, 10, 873-877. | 0.6 | 55 |
| 80 | Parvovirus B19 outbreak on an adult ward. <i>Epidemiology and Infection</i> , 1994, 113, 345-353. | 1.0 | 54 |
| 81 | Influenza among U.K. Pilgrims to Hajj, 2003. <i>Emerging Infectious Diseases</i> , 2004, 10, 1882-1883. | 2.0 | 54 |
| 82 | Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. <i>The Lancet Healthy Longevity</i> , 2021, 2, e811-e819. | 2.0 | 54 |
| 83 | Influenza A antigen exposure selects dominant V β 217+ TCR in human CD8+ cytotoxic T cell responses. <i>International Immunology</i> , 2001, 13, 1373-1381. | 1.8 | 53 |
| 84 | Alterations in Receptor Binding Properties of Recent Human Influenza H3N2 Viruses Are Associated with Reduced Natural Killer Cell Lysis of Infected Cells. <i>Journal of Virology</i> , 2007, 81, 11170-11178. | 1.5 | 52 |
| 85 | Toward unified molecular surveillance of RSV: A proposal for genotype definition. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 274-285. | 1.5 | 52 |
| 86 | An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans. <i>Vaccine Journal</i> , 2014, 21, 1153-1163. | 3.2 | 51 |
| 87 | Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. <i>British Journal of General Practice</i> , 2020, 70, e890-e898. | 0.7 | 51 |
| 88 | Population estimates of persons presenting to general practitioners with influenza-like illness, 1987-1996: a study of the demography of influenza-like illness in sentinel practice networks in England and Wales, and in The Netherlands. <i>Epidemiology and Infection</i> , 2000, 124, 245-253. | 1.0 | 50 |
| 89 | The Evolution of Norovirus, the "Gastric Flu". <i>PLoS Medicine</i> , 2008, 5, e42. | 3.9 | 50 |
| 90 | Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. <i>Epidemiology and Infection</i> , 2013, 141, 620-630. | 1.0 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 638-646. | 1.5 | 49 |
| 92 | Monitoring the emergence of community transmission of influenza A/H1N1 2009 in England: a cross sectional opportunistic survey of self sampled telephone callers to NHS Direct. <i>BMJ: British Medical Journal</i> , 2009, 339, b3403-b3403. | 2.4 | 48 |
| 93 | Urgent challenges in implementing live attenuated influenza vaccine. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e25-e32. | 4.6 | 46 |
| 94 | The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19773. | 1.2 | 44 |
| 95 | Current research on respiratory viral infections: Fourth International Symposium. <i>Antiviral Research</i> , 2002, 55, 227-278. | 1.9 | 43 |
| 96 | Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 171-182. | 1.5 | 43 |
| 97 | Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. <i>Journal of Virology</i> , 2019, 93, . | 1.5 | 42 |
| 98 | Harmonizing influenza primary-care surveillance in the United Kingdom: piloting two methods to assess the timing and intensity of the seasonal epidemic across several general practice-based surveillance schemes. <i>Epidemiology and Infection</i> , 2015, 143, 1-12. | 1.0 | 41 |
| 99 | Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom1. <i>Emerging Infectious Diseases</i> , 2011, 17, 990-999. | 2.0 | 41 |
| 100 | Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 647-657. | 1.5 | 40 |
| 101 | Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. <i>Journal of Infection and Public Health</i> , 2016, 9, 231-235. | 1.9 | 36 |
| 102 | Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. <i>Journal of Infection</i> , 2020, 81, 785-792. | 1.7 | 36 |
| 103 | Mortality Attributable to Influenza in England and Wales Prior to, during and after the 2009 Pandemic. <i>PLoS ONE</i> , 2013, 8, e79360. | 1.1 | 36 |
| 104 | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18. <i>Eurosurveillance</i> , 2019, 24, . | 3.9 | 36 |
| 105 | Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43.) <i>Tj ETQq1 1 0,784314 rgBT /Overld</i> | 0,9 | 35 |
| 106 | Evolutionary Pathways of the Pandemic Influenza A (H1N1) 2009 in the UK. <i>PLoS ONE</i> , 2011, 6, e23779. | 1.1 | 34 |
| 107 | A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. <i>Influenza and Other Respiratory Viruses</i> , 2009, 3, 107-117. | 1.5 | 33 |
| 108 | Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families. <i>European Journal of Pediatrics</i> , 2008, 167, 395-399. | 1.3 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Probable Vertical Transmission of SARS-CoV-2 Infection. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e257-e260. | 1.1 | 32 |
| 110 | Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance—opportunities and challenges. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 622-629. | 1.5 | 31 |
| 111 | Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England. <i>Journal of Infection</i> , 2020, 81, 427-434. | 1.7 | 31 |
| 112 | Linking syndromic surveillance with virological self-sampling. <i>Epidemiology and Infection</i> , 2008, 136, 222-224. | 1.0 | 30 |
| 113 | Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100038. | 3.0 | 30 |
| 114 | Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. <i>Transfusion</i> , 2021, 61, 2837-2843. | 0.8 | 29 |
| 115 | Enhanced MERS Coronavirus Surveillance of Travelers from the Middle East to England. <i>Emerging Infectious Diseases</i> , 2014, 20, 1562-1564. | 2.0 | 27 |
| 116 | SARS transmission in Vietnam outside of the health-care setting. <i>Epidemiology and Infection</i> , 2007, 135, 392-401. | 1.0 | 26 |
| 117 | Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009–2010. <i>Emerging Infectious Diseases</i> , 2011, 17, 1807-1815. | 2.0 | 26 |
| 118 | Seroprevalence of Influenza A(H1N1)pdm09 Virus Antibody, England, 2010 and 2011. <i>Emerging Infectious Diseases</i> , 2012, 18, 1894-7. | 2.0 | 25 |
| 119 | Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. <i>Journal of Immunological Methods</i> , 2017, 449, 1-6. | 0.6 | 25 |
| 120 | Response to influenza virus vaccination in vertical HIV infection. <i>Archives of Disease in Childhood</i> , 1997, 76, 215-218. | 1.0 | 24 |
| 121 | Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort. <i>Wellcome Open Research</i> , 2020, 5, 98. | 0.9 | 24 |
| 122 | SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 3.9 | 24 |
| 123 | Serological surveillance of influenza in an English sentinel network: pilot study protocol. <i>BMJ Open</i> , 2019, 9, e024285. | 0.8 | 23 |
| 124 | Favipiravir-resistant influenza A virus shows potential for transmission. <i>PLoS Pathogens</i> , 2021, 17, e1008937. | 2.1 | 23 |
| 125 | Cohort Profile: The Flu Watch Study. <i>International Journal of Epidemiology</i> , 2016, 46, dyv370. | 0.9 | 22 |
| 126 | Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24341. | 1.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | First external quality assurance of antibody diagnostic for SARS-new coronavirus. <i>Journal of Clinical Virology</i> , 2005, 34, 22-25. | 1.6 | 21 |
| 128 | Estimating the burden on general practitioner services in England from increases in respiratory disease associated with seasonal respiratory pathogen activity. <i>Epidemiology and Infection</i> , 2018, 146, 1389-1396. | 1.0 | 21 |
| 129 | Personal Protective Equipment and Risk for Avian Influenza (H7N3). <i>Emerging Infectious Diseases</i> , 2009, 15, 59-62. | 2.0 | 20 |
| 130 | Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e220-e234. | 5.9 | 20 |
| 131 | Self-sampling for community respiratory illness: a new tool for national virological surveillance. <i>Eurosurveillance</i> , 2015, 20, 21058. | 3.9 | 19 |
| 132 | Nosocomial transmission of influenza: A retrospective cross-sectional study using next generation sequencing at a hospital in England (2012-2014). <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 556-563. | 1.5 | 18 |
| 133 | Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England. <i>Journal of Infection</i> , 2021, 83, 573-580. | 1.7 | 18 |
| 134 | Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort. <i>Wellcome Open Research</i> , 2020, 5, 98. | 0.9 | 18 |
| 135 | Epidemiological and clinical characteristics of early COVID-19 cases, United Kingdom of Great Britain and Northern Ireland. <i>Bulletin of the World Health Organization</i> , 2021, 99, 178-189. | 1.5 | 18 |
| 136 | Nucleic Acid Dipstick Test for Molecular Diagnosis of Pandemic H1N1. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3608-3613. | 1.8 | 17 |
| 137 | Developments in the treatment of severe influenza. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 560-565. | 1.3 | 17 |
| 138 | Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. <i>Clinical Infectious Diseases</i> , 2020, 71, 2872-2879. | 2.9 | 17 |
| 139 | SARS-CoV-2 infection, antibody positivity and seroconversion rates in staff and students following full reopening of secondary schools in England: A prospective cohort study, September-December 2020. <i>EClinicalMedicine</i> , 2021, 37, 100948. | 3.2 | 17 |
| 140 | Fatal Cases of Influenza A(H3N2) in Children: Insights from Whole Genome Sequence Analysis. <i>PLoS ONE</i> , 2012, 7, e33166. | 1.1 | 17 |
| 141 | The inexact science of influenza prediction. <i>Lancet, The</i> , 2004, 363, 582-583. | 6.3 | 16 |
| 142 | Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. <i>Antiviral Research</i> , 2010, 86, 128-136. | 1.9 | 16 |
| 143 | The potential risks and impact of the start of the 2015-2016 influenza season in the WHO European Region: a rapid risk assessment. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 236-246. | 1.5 | 16 |
| 144 | Development of vaccines against common colds. <i>British Medical Bulletin</i> , 2002, 62, 99-111. | 2.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Antibody capture haemadherence tests for parvovirus B19-specific IgM and IgG. <i>Journal of Virological Methods</i> , 1993, 45, 27-37. | 1.0 | 14 |
| 146 | Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. <i>Antiviral Research</i> , 2011, 90, 205-212. | 1.9 | 14 |
| 147 | The burden of seasonal respiratory infections on a national telehealth service in England. <i>Epidemiology and Infection</i> , 2017, 145, 1922-1932. | 1.0 | 13 |
| 148 | Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016â€“2017 and 2017â€“2018 Influenza Seasons in the United Kingdom. <i>Clinical Infectious Diseases</i> , 2020, 70, 2505-2513. | 2.9 | 13 |
| 149 | Microbiological aspects of public health planning and preparedness for the 2012 Olympic Games. <i>Epidemiology and Infection</i> , 2012, 140, 2142-2151. | 1.0 | 12 |
| 150 | Active and passive immunisation against respiratory syncytial virus. , 1999, 9, 227-236. | | 11 |
| 151 | Experience with the clinical development of influenza vaccines for potential pandemics. <i>Medical Microbiology and Immunology</i> , 2002, 191, 197-201. | 2.6 | 11 |
| 152 | Sentinel surveillance of influenza in Europe 1997-1998. <i>Eurosurveillance</i> , 1998, 3, 29-31. | 3.9 | 11 |
| 153 | Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 723-30. | 0.4 | 11 |
| 154 | Lessons from the 1918 influenza. <i>Nature Biotechnology</i> , 2007, 25, 433-434. | 9.4 | 10 |
| 155 | Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03A-Adjuvanted H1N1 2009 Vaccine. <i>PLoS ONE</i> , 2013, 8, e47448. | 1.1 | 10 |
| 156 | Mass testing after a single suspected or confirmed case of COVID-19 in London care homes, Aprilâ€“May 2020: implications for policy and practice. <i>Age and Ageing</i> , 2021, 50, 649-656. | 0.7 | 10 |
| 157 | The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. <i>Eurosurveillance</i> , 2021, 26, . | 3.9 | 10 |
| 158 | A single radial haemolysis assay for antibody to H5 haemagglutinin. <i>International Congress Series</i> , 2001, 1219, 761-766. | 0.2 | 9 |
| 159 | Administration of AS03B-adjuvanted A(H1N1)pdm09 Vaccine in Children Aged <3 Years Enhances Antibody Response to H3 and B Viruses Following a Single Dose of Trivalent Vaccine One Year Later. <i>Clinical Infectious Diseases</i> , 2014, 58, 181-187. | 2.9 | 9 |
| 160 | The emergence of enterovirus D68 in England in autumn 2014 and the necessity for reinforcing enterovirus respiratory screening. <i>Epidemiology and Infection</i> , 2017, 145, 1855-1864. | 1.0 | 9 |
| 161 | A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. <i>Health Technology Assessment</i> , 2010, 14, 193-334. | 1.3 | 9 |
| 162 | Influenza surveillance in England and Wales: October 1999 to May 2000. <i>Communicable Disease and Public Health / Phls</i> , 2000, 3, 261-6. | 0.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. <i>Antiviral Research</i> , 2019, 163, 70-74. | 1.9 | 8 |
| 164 | Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England. <i>EClinicalMedicine</i> , 2021, 41, 101150. | 3.2 | 8 |
| 165 | Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England. <i>EClinicalMedicine</i> , 2022, 45, 101319. | 3.2 | 8 |
| 166 | Update on influenza and other viral pneumonias. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 199-204. | 1.3 | 7 |
| 167 | Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2324-2331. | 1.3 | 7 |
| 168 | Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 671-677. | 1.5 | 7 |
| 169 | Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study. <i>Diagnostic and Prognostic Research</i> , 2021, 5, 4. | 0.8 | 7 |
| 170 | Household transmission of seasonal coronavirus infections: Results from the Flu Watch cohort study. <i>Wellcome Open Research</i> , 2020, 5, 145. | 0.9 | 7 |
| 171 | Influenza surveillance in England and Wales: October 1997 to June 1998. <i>Communicable Disease and Public Health / Phls</i> , 1998, 1, 244-51. | 0.3 | 7 |
| 172 | Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children. <i>Clinical and Experimental Immunology</i> , 2020, 199, 109-118. | 1.1 | 6 |
| 173 | Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV. <i>Vaccine</i> , 2020, 38, 2660-2670. | 1.7 | 6 |
| 174 | Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study. <i>Journal of Infection</i> , 2021, , . | 1.7 | 6 |
| 175 | Influenza surveillance in England and Wales: October 1995 to June 1996. <i>Communicable Disease Report CDR Review</i> , 1996, 6, R163-9. | 0.3 | 6 |
| 176 | Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 142-153. | 1.5 | 5 |
| 177 | Laboratory containment for influenza A H5N1 virus: level 2, level 3, or level 3+?. <i>Communicable Disease and Public Health / Phls</i> , 1998, 1, 71-2. | 0.3 | 5 |
| 178 | Influenza activity in England and Wales: October 1998 to June 1999. <i>Communicable Disease and Public Health / Phls</i> , 1999, 2, 273-9. | 0.3 | 5 |
| 179 | Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children. <i>Clinical and Experimental Immunology</i> , 2021, 204, 125-133. | 1.1 | 4 |
| 180 | Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England. <i>PLoS ONE</i> , 2022, 17, e0262515. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Reply to Skowronski et al.. Journal of Infectious Diseases, 2006, 193, 900-901. | 1.9 | 3 |
| 182 | Can defective interfering RNAs affect the live attenuated influenza vaccine? â€“ Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 1235-1236. | 4.6 | 3 |
| 183 | Invasive Mycobacterium chimaera Infections and Heaterâ€“Cooler Devices in Cardiac Surgery. Emerging Infectious Diseases, 2020, 26, 632-632. | 2.0 | 3 |
| 184 | Influenza surveillance in England and Wales: October 1996 to June 1997. Communicable Disease Report CDR Review, 1997, 7, R212-9. | 0.3 | 3 |
| 185 | A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, . | 1.9 | 3 |
| 186 | Developing vaccines against potential pandemic influenza viruses. International Congress Series, 2001, 1219, 751-759. | 0.2 | 2 |
| 187 | Epidemiological features of a new strain of the influenza A virusâ€“influenza A (H1N2) circulating in England and its public health implications. Virus Research, 2004, 103, 53-54. | 1.1 | 2 |
| 188 | Influenza surveillance in England and Wales: October 1994 to June 1995. Communicable Disease Report CDR Review, 1995, 5, R200-4. | 0.3 | 2 |
| 189 | Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdomâ€™s COVID-19 Public Health Response. Microbiology Spectrum, 2022, 10, e0228921. | 1.2 | 2 |
| 190 | The Immunogenicity of a Cellâ€“derived H7N1 Split Influenza Virion Vaccine in Mice. Scandinavian Journal of Immunology, 2009, 69, 576-578. | 1.3 | 1 |
| 191 | Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1) â€“ Authors' reply. Lancet Infectious Diseases, The, 2011, 11, 497-498. | 4.6 | 1 |
| 192 | Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study. JMIR Public Health and Surveillance, 2022, 8, e25803. | 1.2 | 1 |
| 193 | Strain designation for influenza viruses. Communicable Disease and Public Health / Phls, 1999, 2, 157-9. | 0.3 | 1 |
| 194 | Fifty years of influenza surveillance. Communicable Disease and Public Health / Phls, 1999, 2, 81-2. | 0.3 | 0 |
| 195 | Perspectives in interpandemic influenza. IDrugs: the Investigational Drugs Journal, 2007, 10, 861-4. | 0.7 | 0 |